Phase 3 MRI Clinical Trials
6 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–6 of 6 trials
Recruiting
Phase 3
A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Central Nervous System (CNS) Lesions
For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions
Shanghai Shengdi Pharmaceutical Co., Ltd250 enrolled2 locationsNCT07275814
Recruiting
Phase 3
A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Body Parts (Non-Central Nervous System) Lesions
For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Abnormal Vascular Lesions in Body Regions Excluding the Central Nervous System (CNS)
Shanghai Shengdi Pharmaceutical Co., Ltd306 enrolled2 locationsNCT07275723
Recruiting
Phase 2Phase 3
Effects of Ketone Supplement and Alcohol on Brain Metabolism
MRIKetosisAlcohol Drinking
University of Pennsylvania60 enrolled1 locationNCT06815237
Active
Phase 3Phase 4
Investigation of the Effects of Longvida Curcumin on Cognitive Function, Mood and Biomarkers of Health.
Brain function (fMRI)Psychological wellbeing (mood, stress fatigue, sleep)Inflammation+2 more
Swinburne University of Technology, Centre for Human Psychopharmacology80 enrolled1 locationACTRN12616000484448
Not Yet Recruiting
Phase 3Phase 4
Investigation into the Acute and Chronic Effects of Longvida Curcumin on Cognitive Function, Mood and Biomarkers of Health in an Elderly Population.
Mood, stress and fatigueInflamationCerebral Blood Flow (fMRI)
Swinburne University of Technology, Centre for Human Psychopharmacology60 enrolled1 locationACTRN12612001027808
Completed
Phase 3
A clinical study to determine the safety and efficacy of gadobutrol 1.0 molar (Gadovist 'Registered trade mark') in comparison to ProHance 'Registered trade mark' (gadoteridol) 0.5 molar in patients referred for contrast-enhanced Magnetic Resonance Imaging (MRI) of the central nervous system.
Central nervous system diseases requiring a contrast-enhanced MRI of the CNS.
Bayer Australia Ltd402 enrolled7 locationsACTRN12608000455369